Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil

Stopped early · Phase 1

Conditions studied: Lupus Nephritis

In brief

The sponsor electively terminated the study because the risk mitigation measures, deemed necessary after an unforeseen safety event, could not be effectively implemented within this protocol while maintaining study timelines within a reasonable time frame.

Key facts

Study ID

NCT01369628

Run by

EMD Serono

People needed

1

Starts

2011-06-01

Last updated by the study team

2013-10-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female subjects, ≥ 18 years of age, who provide written informed consent
• Subjects must have a diagnosis of SLE satisfying ≥ 4 of 11 ACR criteria, and must have had a renal biopsy during screening or within the previous 18 months demonstrating class III (A or A/C), IV (A or A/C), V, or concomitant III/V or IV/V LN as defined by the International Society of Nephrology/Renal Pathology Society (ISN/RPS).
• Subjects must have a urine protein: creatinine ratio ≥ 2 mg/mg (≥ 226.2 mg/mmol), and either a positive test for antinuclear antibody (ANA) (HEp-2 ANA ≥ 1:80) and/or anti-double stranded deoxyribonucleic acid (dsDNA) (≥ 30 IU/mL) at screening.
• Subjects must have started induction therapy for LN at least 5 months prior to Trial Day 1, be considered to have received continuous treatment for LN during the 5 months prior to Trial Day 1, and have received a stable dose of MMF ≥ 1 g/day, with or without corticosteroids, for at least 8 weeks prior to Trial Day 1.

You may not qualify if…

• Recent changes in immunosuppressant, ACD inhibitors for ARBs
• Use of azathioprine, cyclosporine, tacrolimus, or cyclophosphamide or other biologics within 8 weeks prior to Trial Day 1.
• Serum IgG < 6 g/L
• Estimated Glomerular Filtration Rate (GFR) ≤ 30 mL/min per 1.73 m2
• History of Demyelinating Disease
• Significant Hematuria and/or Proteinuria due to a reason(s) other than LN. Evaluation should be done according to the local standard of care
• Breast feed or pregnancy
• Legal Incapacity or limited legal capacity

Where it is running

• EMD Serono Inc., One Technology Place — Rockland, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.